C. P. Carden

554 total citations
8 papers, 358 citations indexed

About

C. P. Carden is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, C. P. Carden has authored 8 papers receiving a total of 358 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 3 papers in Cancer Research. Recurrent topics in C. P. Carden's work include Radiopharmaceutical Chemistry and Applications (2 papers), BRCA gene mutations in cancer (2 papers) and Cancer, Hypoxia, and Metabolism (2 papers). C. P. Carden is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (2 papers), BRCA gene mutations in cancer (2 papers) and Cancer, Hypoxia, and Metabolism (2 papers). C. P. Carden collaborates with scholars based in United Kingdom and United States. C. P. Carden's co-authors include Johann S. de Bono, Peter C.C. Fong, Ioanna Ledaki, R. Molife, David P. Dearnaley, Joo Ern Ang, Gerhardt Attard, Leon W.M.M. Terstappen, Hendrik‐Tobias Arkenau and David Olmos and has published in prestigious journals such as Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

C. P. Carden

8 papers receiving 353 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. P. Carden United Kingdom 6 213 140 139 104 46 8 358
Mariangela Zanghì Italy 7 234 1.1× 211 1.5× 79 0.6× 144 1.4× 29 0.6× 12 414
Joseph W. Po Australia 12 155 0.7× 60 0.4× 140 1.0× 112 1.1× 13 0.3× 15 320
Malgorzata Banys-Paluchowski Germany 16 270 1.3× 96 0.7× 249 1.8× 131 1.3× 88 1.9× 46 519
Walid Basher Israel 7 268 1.3× 57 0.4× 90 0.6× 85 0.8× 27 0.6× 9 446
J. H. Finke United States 6 175 0.8× 65 0.5× 145 1.0× 97 0.9× 9 0.2× 9 395
Tatsuya Shimomura Japan 9 173 0.8× 265 1.9× 87 0.6× 203 2.0× 8 0.2× 37 469
E Sivridis Greece 9 152 0.7× 68 0.5× 103 0.7× 189 1.8× 56 1.2× 19 387
Nina Seitzer United States 7 193 0.9× 106 0.8× 76 0.5× 266 2.6× 20 0.4× 9 431
Magnus Zethoven Australia 14 192 0.9× 111 0.8× 145 1.0× 213 2.0× 18 0.4× 21 501
Mai Tomiguchi Japan 12 146 0.7× 80 0.6× 272 2.0× 280 2.7× 9 0.2× 24 490

Countries citing papers authored by C. P. Carden

Since Specialization
Citations

This map shows the geographic impact of C. P. Carden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. P. Carden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. P. Carden more than expected).

Fields of papers citing papers by C. P. Carden

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. P. Carden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. P. Carden. The network helps show where C. P. Carden may publish in the future.

Co-authorship network of co-authors of C. P. Carden

This figure shows the co-authorship network connecting the top 25 collaborators of C. P. Carden. A scholar is included among the top collaborators of C. P. Carden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. P. Carden. C. P. Carden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Carden, C. P., Robin L. Jones, Salma Alam, et al.. (2010). Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF- 1R) and insulin receptor (IR) in patients with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 2530–2530. 27 indexed citations
2.
Papadatos-Pastos, D., Montserrat Blanco-Codesido, C. P. Carden, et al.. (2010). Should patients with malignant intracranial space occupying lesions (M-ICSOLs) be excluded from phase I trials? The Royal Marsden Hospital Drug Development Unit experience.. Journal of Clinical Oncology. 28(15_suppl). 2516–2516. 3 indexed citations
3.
Yap, Tami, C. P. Carden, J. Carmichael, et al.. (2010). Preliminary experience with the use of chemotherapy (CT) following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in patients with BRCA1/2-deficient ovarian cancer (BDOC).. Journal of Clinical Oncology. 28(15_suppl). 5041–5041. 12 indexed citations
4.
5.
Olmos, David, Hendrik‐Tobias Arkenau, Joo Ern Ang, et al.. (2008). Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Annals of Oncology. 20(1). 27–33. 194 indexed citations
6.
Nathan, Paul, Ian Judson, Adrian L. Harris, et al.. (2008). A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. Journal of Clinical Oncology. 26(15_suppl). 3550–3550. 37 indexed citations
7.
Carden, C. P., Florence I. Raynaud, Robin L. Jones, et al.. (2008). Crossover pharmacokinetics (PK) study to assess oral administration of abiraterone acetate capsule and tablet formulations in fasted and fed states in patients with prostate cancer. Journal of Clinical Oncology. 26(15_suppl). 5168–5168. 5 indexed citations
8.
Fong, Peter C.C., David S. Boss, C. P. Carden, et al.. (2008). AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study. Journal of Clinical Oncology. 26(15_suppl). 5510–5510. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mariangela Zanghì Breakdown of academic impact, for papers by Joseph W. Po Breakdown of academic impact, for papers by Malgorzata Banys-Paluchowski Breakdown of academic impact, for papers by Walid Basher Breakdown of academic impact, for papers by J. H. Finke Breakdown of academic impact, for papers by Tatsuya Shimomura Breakdown of academic impact, for papers by E Sivridis Breakdown of academic impact, for papers by Nina Seitzer Breakdown of academic impact, for papers by Magnus Zethoven Breakdown of academic impact, for papers by Mai Tomiguchi
Rankless by CCL
2026